Physicochemical Properties
| Molecular Formula | C14H16O4S |
| Molecular Weight | 280.34 |
| Exact Mass | 280.077 |
| Elemental Analysis | C, 59.98; H, 5.75; O, 22.83; S, 11.44 |
| CAS # | 101973-77-7 |
| PubChem CID | 127998 |
| Appearance | Solid powder |
| Density | 1.241g/cm3 |
| Boiling Point | 477.7ºC at 760mmHg |
| Flash Point | 242.7ºC |
| Vapour Pressure | 6.18E-10mmHg at 25°C |
| Index of Refraction | 1.567 |
| LogP | 2.548 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 19 |
| Complexity | 345 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC1=CC=C(C(CC(CSC(C)=O)C(O)=O)=O)C=C1 |
| InChi Key | YRSSFEUQNAXQMX-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C14H16O4S/c1-9-3-5-11(6-4-9)13(16)7-12(14(17)18)8-19-10(2)15/h3-6,12H,7-8H2,1-2H3,(H,17,18) |
| Chemical Name | Benzenebutanoic acid, alpha-((acetylthio)methyl)-4-methyl-gamma-oxo- |
| Synonyms | Esonarimod KE-298 KE298 KE 298 Related CAS# |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In a dose-dependent manner, esonarimod (KE-298) (10 to 300 μg/mL) suppresses NO generation in RAW264.7 cells. Esonarimod has an IC50 of 117.5 μg/mL. Cell viability remained unaffected by exonamod at the studied dosages. Exonamod does not directly affect NOS activity in RAW264.7 cell-free extracts [1]. |
| ln Vivo | Following several oral doses of Esonarimod (14C-KE-298), there was a quick drop in radioactivity and no discernible accumulation trend [2]. |
| References |
[1]. Inoue T, et al. KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis. J Rheumatol. 2001 Jun;28(6):1229-37. [2]. Hasegawa M, et al. Formation of a disulfide protein conjugate of the SH-group-containing metabolite (M-I) ofesonarimod (KE-298) and its elimination in rats. J Pharm Pharmacol. 2002 Apr;54(4):493-8 |
| Additional Infomation | Esonarimod is an aromatic ketone. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~356.71 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5671 mL | 17.8355 mL | 35.6710 mL | |
| 5 mM | 0.7134 mL | 3.5671 mL | 7.1342 mL | |
| 10 mM | 0.3567 mL | 1.7835 mL | 3.5671 mL |